WHO ICTRP trial
Study of efficacy and safety of capmatinib in combination with pembrolizumab…
JPRN-jRCT2080225053 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080225053 |
|---|---|
| Public title | Study of efficacy and safety of capmatinib in combination with pembrolizumab versus pembrolizumab alone in subjects with non-small cell lung cancer with PD-L1>= 50% |
| Scientific title | A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1>= 50% |
| Primary sponsor | Novartis Pharma. K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Japan;Asia except Japan;North America;Europe;Oceania |
| Conditions | Non small cell lung cancer (NSCLC) |
| Interventions | investigational material(s) Generic name etc : INN of investigational material : Capmatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc… |
| Registration date | Jun 2, 2020 |
| Target size | 96 |
| Secondary IDs | NCT04139317;JapicCTI-205148 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: